The copper¹ sequestering³（隔绝，隔离） drug tetrathiomolybdate（钼酸盐） (TM) has been shown in studies to be effective in the treatment of Wilson disease, a disease caused by an overload⁴ of copper, and certain metastatic cancers（性肿瘤）. That much is known. Very little, however, is known about how the drug works at the molecular⁵ level. A new study led by Northwestern University researchers now has provided an invaluable⁶ clue: the three-dimensional structure of TM bound to copper-loaded metallochaperones. The drug sequesters⁷ the chaperone（伴侣蛋白） and its bound copper, preventing both from carrying out their normal functions in the cell. For patients with Wilson disease and certain cancers whose initial growth is helped by copper-dependent angiogenesis（血管生成）, this is very promising⁸.

This knowledge opens the door to the development of new classes of pharmaceutical⁹ agents based on metal trafficking pathways, as well as the further development of more efficient TM-based drugs. The study will be published in Science Express Nov. 26.

"Essential metals are at the center of many emerging problems in health, medicine and the environment, and this work opens the door to new biological experiments," said Thomas V. O'Halloran, the study's senior author and the Charles E. and Emma H. Morrison Professor of Chemistry in the Weinberg College of Arts and Sciences at Northwestern. He and geneticist Valeria Culotta of Johns Hopkins University discovered the first copper chaperone function in 1997.

O'Halloran and his research team studied the copper chaperone protein Atx1, which provides a good model of copper metabolism¹⁰（新陈代谢） in animal cells. "We wondered what the drug tetrathiomolybdate did to copper chaperones -- proteins charged with safely ferrying copper within the cell -- and what we found was most amazing," O'Halloran said. "The drug brings three copper chaperones into close quarters, weaving them together through an intricate（错综的，复杂的） metal-sulfur¹¹ cluster（串，丛，群） in a manner that essentially¹² shuts down the copper ferrying system."

The nest-shaped structure of the metal-sulfur cluster discovered by the researchers was completely unanticipated.

"When we mixed TM together with copper chaperone proteins in a test tube, the color of the solution changed from light orange to deep purple," said Hamsell M. Alvarez, the paper's first author and a former doctoral student in O'Halloran's lab, now with Merck & Co., Inc. "The sulfur atoms in the tetrathiomolybdate bound to the copper atoms to form an open cluster that bridged the chaperone proteins. In this manner, three copper proteins were jammed onto one thiomolybdate."

Alfonso Mondragón, professor of biochemistry, molecular biology and cell biology in the Weinberg College of Arts and Sciences, and graduate student Yi Xue, both co-authors of the paper, solved the three-dimensional crystal structure using protein X-ray crystallography. This is the first example of a copper-sulfide-molybdenum metal cluster protein.

Based on the structure and additional experiments, the scientists propose that the drug inhibits¹³ the traffic of copper within the cell because of its ability to sequester² copper chaperones and their cargo¹⁴ in clusters, rendering¹⁵（表现，渲染） the copper inactive.